LUCC: Lund University Cancer Centre
41 – 50 of 3248
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Nasogastric tube after oesophagectomy and risk of anastomotic leak : a Nordic, multicentre, open-label, randomised, controlled, non-inferiority trial
(
- Contribution to journal › Article
-
Mark
Omental preservation versus omentectomy in curative-intent gastrectomy for gastric cancer : Swedish population-based cohort study
(
- Contribution to journal › Article
-
Mark
Speedy A governs non-homologous XY chromosome desynapsis as a unique prerequisite for XY loop-axis organization
(
- Contribution to journal › Article
-
Mark
Pancreatic Adenocarcinoma : Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
(
- Contribution to journal › Article
-
Mark
Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
(
- Contribution to journal › Article
-
Mark
Comparative Clinical and Imaging-Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification
(
- Contribution to journal › Article
-
Mark
Incidence of and Risk Factors for Cutaneous Malignant Neoplasms after Blood or Marrow Transplant
(
- Contribution to journal › Article
-
Mark
Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC) : Considerations from the European Association of Urology NMIBC Guideline Panel
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mutations in GFAP Alter Early Lineage Commitment of Organoids
(
- Contribution to journal › Article
-
Mark
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy : Results from the prospective GHSG–NLG phase II BVB trial
(
- Contribution to journal › Letter